Artiva Biotherapeutics, a biotherapeutics developer specializing in NK cell therapy, highlighted its progress at the Stifel 2026 Virtual Immunology and Inflammation Forum, underscoring clinical and manufacturing advancements in autoimmune and oncology indications. Founded in 2019 and treating its first oncology patient in 2021, the company has raised $300 million since May 2024, extending its funding runway through 2029. A randomized Phase III trial comparing its NK cell therapy to rituximab monotherapy is expected to deliver a readout before the end of 2028, with over 150 patients planned in the study.
The therapy targets refractory rheumatoid arthritis, Sjogren’s syndrome, systemic sclerosis, and hematological malignancies, including non-Hodgkin’s and Hodgkin’s lymphoma. Early data show promising response rates: a 71% ACR50 response rate in 20 rheumatoid arthritis patients, compared to a standard-of-care range of 10%–20% in refractory cases. Three patients achieved 12 months of durability without additional therapy. Safety profiles are robust, with no cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome among the first 55 patients, and only two hospitalizations linked to unrelated conditions.
Artiva’s dosing regimen involves five intravenous visits over four weeks, including preconditioning with cyclophosphamide and fludarabine, followed by rituximab and NK cell infusions. The company’s manufacturing process leverages umbilical cord units, producing enough therapy to treat over 500 patients per unit. A 9,000-square-foot facility in San Diego supports its operations, with a current ratio of 24.16 and negative leveraged free cash flow of $77 million over the past year. At scale, each treatment course costs approximately $8,000.
CEO Fred Aslan emphasized the advantages of NK cells over T-cell therapies, noting lower side-effect risks and the ability to administer treatments in community settings. The company’s stock, which closed at $7.45 on September 24, 2026, had fallen 3.5% from $7.72 the prior day, reflecting an 8.5% drop over the prior week and a 168% surge over the past year. The ticker’s 52-week range spans $2.71 to $14.53, with a beta of 2.2.
Artiva’s strategy aligns with broader trends in deep B-cell depletion, a mechanism first demonstrated with CAR T-cell therapies but now pursued with NK cells. While higher NK cell doses require scalable manufacturing, Aslan highlighted the backbone process’s consistency since 2021, positioning the company for potential regulatory approvals and commercialization in the coming years.
